Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody - Calicheamicin conjugate for treatment of acute myeloid leukemia

Bioconjugate Chemistry

Volumn 13, Issue 1, 2002, Pages 47-58

  Hamann, Philip R ^a   Hinman, Lois M ^a   Hollander, Irwin ^a   Beyer, Carl F ^a   Lindh, Delores ^a   Holcomb, Ryan ^a   Hallett, William ^a   Tsou, Hwei Ru ^a   Upeslacis, Janis ^a   Shochat, Dan ^a   Mountain, Andrew ^b   Flowers, David A ^c   Bernstein, Irwin ^c  

^a PFIZER INC   (United States)

^b UCB PHARMA   (Belgium)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARBOHYDRATES; DISEASES; PATIENT TREATMENT; STEM CELLS; TISSUE CULTURE;

ACUTE MYELOID LEUKEMIA; BI-FUNCTIONAL; CALICHEAMICIN; CLINICAL TRIAL; CYTOTOXIC; HAEMATOPOIETIC STEM CELLS; HYDRAZONES; LEUKAEMIA CELLS; MYELOID LEUKAEMIA CELLS; PERIODATE OXIDATION;

ANTIBODIES;

MURINAE;

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CD33 ANTIGEN; CROSS LINKING REAGENT; DIFFERENTIATION ANTIGEN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GEMTUZUMAB; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE DISEASE; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL STRAIN HL 60; HUMAN; IMMUNOLOGY; MOUSE; MYELOID LEUKEMIA; NUDE MOUSE;

ACUTE DISEASE; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CROSS-LINKING REAGENTS; HL-60 CELLS; HUMANS; IMMUNOTOXINS; INDICATORS AND REAGENTS; LEUKEMIA, MYELOID; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 0036007596     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc010021y     Document Type: Article

References (36)

1. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies
2. I
3. Calicheamicins: Discovery, structure, chemistry, and interaction with DNA
4. The development of antibody delivery systems to target cancer with highly potent maytansinoids
5. Enhancement of the selectivity and antitumor activity of a CC-1065 analogue through immunoconjugate formation
6. Acute leukemia
7. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
8. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
9. Expression of normal myeloid-associate antigens by acute leukemia cells
10. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
11. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model
12. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia
13. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed
14. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
15. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia
16. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia
17. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195
18. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model
19. Cure of xenografted human carcinomas by Br96-doxorubicin immunoconjugates
20. I
21. 1 with glutathione in the presence of double-stranded DNA
22. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia; Choice of linker
23. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations
24. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
25. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
26. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
27. Humanization of an anti-mucin antibody for breast and ovarian cancer therapy
28. Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast cancer cells
29. Preparation of conjugates to monoclonal antibodies
30. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
31. Role of CFTR in lysosome acidification
32. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents